Trials / Completed
CompletedNCT02079207
Study Immunogenicity and Safety of 13-valent Pneumococcal Conjugate Vaccine
Multi-center, Randomized, Double Blinded, Phase III Trial to Assess the Immunogenicity and Safety of NBP606 in Adults 50 Years of Age and Older Who Are naïve to Pneumococcal Vaccine
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 767 (actual)
- Sponsor
- SK Chemicals Co., Ltd. · Industry
- Sex
- All
- Age
- 50 Years
- Healthy volunteers
- Accepted
Summary
This study will assess the Immunogenicity and safety of 13-valent Pneumococcal Conjugate Vaccine compared with 23-valent Pneumococcal Polysaccharide Vaccine. All participants should be naïve of Pneumococcal vaccine.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | NBP606 | 13-valent peumococcal conjugate vaccine(13vPnC) |
| BIOLOGICAL | Prodiax-23 | 23-valent peumococcal polysaccharide vaccine(23vPS) |
Timeline
- Start date
- 2013-12-01
- Primary completion
- 2014-10-01
- Completion
- 2015-03-01
- First posted
- 2014-03-05
- Last updated
- 2016-01-27
Source: ClinicalTrials.gov record NCT02079207. Inclusion in this directory is not an endorsement.